These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20065643)

  • 21. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory policies on medicines for psychiatric disorders: is Europe on target?
    Barbui C; Garattini S
    Br J Psychiatry; 2007 Feb; 190():91-3. PubMed ID: 17267922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
    Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosimilar, biobetter and next generation therapeutic antibodies.
    Beck A
    MAbs; 2011; 3(2):107-10. PubMed ID: 21285536
    [No Abstract]   [Full Text] [Related]  

  • 27. Anti-neoplastic biosimilars--the same rules as for cytotoxic generics cannot be applied.
    Mellstedt H
    Ann Oncol; 2013 Sep; 24 Suppl 5():v23-8. PubMed ID: 23975701
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of specifications for biotechnology products--perspective from Europe.
    Trouvin JH
    Dev Biol Stand; 1997; 91():25-30. PubMed ID: 9413679
    [No Abstract]   [Full Text] [Related]  

  • 30. Monoclonal antibody: the corner stone of modern biotherapeutics.
    Xia ZN; Cai XT; Cao P
    Yao Xue Xue Bao; 2012 Oct; 47(10):1275-80. PubMed ID: 23289138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies to watch in 2020.
    Kaplon H; Muralidharan M; Schneider Z; Reichert JM
    MAbs; 2020; 12(1):1703531. PubMed ID: 31847708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory considerations for generic or biosimilar low molecular weight heparins.
    García-Arieta A; Blázquez A
    Curr Drug Discov Technol; 2012 Jun; 9(2):137-42. PubMed ID: 21838658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biopharmaceutical benchmarks 2018.
    Walsh G
    Nat Biotechnol; 2018 Dec; 36(12):1136-1145. PubMed ID: 30520869
    [No Abstract]   [Full Text] [Related]  

  • 36. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars: policy, clinical, and regulatory considerations.
    Gottlieb S
    Am J Health Syst Pharm; 2008 Jul; 65(14 Suppl 6):S2-8. PubMed ID: 18591712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars and regulatory authorities.
    Minghetti P; Rocco P; Del Vecchio L; Locatelli F
    Nephron Clin Pract; 2011; 117(1):c1-7. PubMed ID: 20689318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Integration of Regulatory Guidelines into Protein Drug Product Development.
    Wang W
    PDA J Pharm Sci Technol; 2016; 70(1):2-11. PubMed ID: 26889052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biopharmaceuticals and biotechnology medicines: an issue of nomenclature.
    Walsh G
    Eur J Pharm Sci; 2002 Mar; 15(2):135-8. PubMed ID: 11849909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.